Invokana (Canagliflozin) Tablets

The journey to triple protection
in type 2 diabetes starts at the kidneys

Invokana offers triple protection in
T2DM against renal events, CV
events and elevated HbA1c1

Invokana is indicated for the treatment of adults with
insufficiently controlled type 2 diabetes mellitus as an
adjunct to diet and exercise:

  • as monotherapy when metformin is considered
    inappropriate due to intolerance or contraindications
  • in addition to other medicinal products for the treatment of
    diabetes

For study results with respect to combination of therapies,
effects on glycaemic control, cardiovascular and renal
events, and the populations studied, see sections 4.4, 4.5 and 5.1 of the SmPC.1

 

Prescribing information can be accessed by clicking the PI links at the bottom of this webpage.

Kidney, heart and blood drop icon image

About Invokana

A Journey to Triple Protection with Invokana

Why Choose Invokana

Kidney symbol with down arrow sign

The first SGLT2i also licensed to treat DKD in T2DM patients with albuminuria UACR
>30 mg/mmol (100 mg dose only)1

Blood droplet with down arrow sign

Invokana eliminates more blood glucose every day than any other SGLT2i1-5

Number of Patient icon

Invokana gets more patients to HbA1c target than any other SGLT2i as add-on to metformin1-4

Heart symbol with down arrow sign

Reduces the risk of major CV events over the long term (up to 6.5 years)6

HCP Resources

This section provides useful resources to help you provide optimal care.

Invokana Article header

Trend UK – Type 2 Diabetes and Chronic Kidney Disease

Doctor talking to a patient

Patient Information

For your patients who have been prescribed Invokana for the treatment of insufficiently controlled type 2 diabetes.

Doctor writing prescription

SGLT2i Prescribing Tool

The Prescribing Tool is a quick reference guide to support clinicians with treatment decisions concerning SGLT2i therapies.

Abbreviations
CV: Cardiovascular; DKD: Diabetic Kidney Disease; HbA1c: Haemoglobin A1c; SGLT2i: Sodium-Glucose Co-Transporter 2 inhibitor; SmPC: Summary of Product Characteristics; T2DM: Type 2 Diabetes Mellitus; UACR: Urinary Albumin/Creatinine Ratio.
References
  • 1. Invokana Summary of Product Characteristics. Napp Pharmaceuticals Limited. Available at: https://www.medicines.org.uk/emc/product/8855/smpc and https:// www.medicines.org.uk/emc/product/12057/smpc[Accessed May 2021].
  • 2. Dapagliflozin Summary of Product Characteristics. AstraZeneca. Available at: https://www.medicines.org.uk/emc/product/7607 [Accessed May 2021].
  • 3. Ertugliflozin Summary of Product Characteristics. Merck Sharp & Dohme. Available at: https://www.medicines.org.uk/emc/product/9803 [Accessed May 2021].
  • 4. Empagliflozin Summary of Product Characteristics. Boehringer Ingelheim. Available at: https://www.medicines.org.uk/emc/product/5441 [Accessed May 2021].
  • 5. Sahasrabudhe V, Terra S, Hickman A, et al. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus. J Clin Pharm. 2017;57(11):1432-1443. doi:10.1002/jcph.955.
  • 6. Neal B, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925.
Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyuk@napp.co.uk.